Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery named Company of the Year at Bionow Annual Awards

Sygnature Discovery is thrilled to announce that we have been named Company of the Year at the Bionow Annual Awards 2020!

The prestigious Bionow Annual Awards were celebrated with a virtual ceremony last night, which brought together the best of the world class life sciences sector to celebrate excellence (and provide a now-rare opportunity to dress up).

Its goal was to highlight the outstanding success and achievements of those who have worked tirelessly this year, and recognise the incredible progress that has been made during this challenging period. The Company of the Year category included a broad criteria that looked at the company’s strategy, expanded services, acquisitions, investment in training, company growth and future plans.

“It is fantastic for Sygnature to be recognised by Bionow in the Life Sciences industry. I believe it acknowledges the sustained contribution of our staff to delivering innovative research to the pharmaceutical industry.”
Dr Paul Overton, Chief Commercial Officer at Sygnature Discovery

Sygnature CEO, Simon Hirst, and XenoGesis CEO, Richard Weaver, celebrate the aquisition of XenoGesis in 2020.

In the last year, Sygnature has been able to continue our fantastic journey of growth and success. By adapting and supporting our scientists, Sygnature has been able to remain fully operational in a safe and sustainable manner throughout 2020 and into 2021. The acquisition of Alderley Oncology and XenoGesis have also been important steps in expanding our capabilities and fulfilling our mission of delivering truly integrated drug discovery solutions.

We are so proud of the team here at Sygnature and their incredible hard work and adaptability during the last year, which has led to tremendous success and growth during such a difficult period. We would also like to thank Bionow for recognising the dedication and innovation of our team in 2020.

For more information on the Bionow Awards, read here.

If you have any questions, would like to find out more about Sygnature Discovery or drug discovery in general then we’d love to hear from you. You can get in touch by using any of the contact forms.

 

Latest News

View All

Sygnature collaborates with Japanese bio-venture company Epigeneron

Five Arrows invests in Sygnature Discovery

Sygnature Discovery expands into early CMC development

Sygnature gains ISO:27001 certification for information security

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.